These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 22222799

  • 1. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
    Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.
    Z Gastroenterol; 2012 Jan; 50(1):57-72. PubMed ID: 22222799
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z, Israeli Association for the Study of the Liver.
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
    Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, Zeuzem S, Sarrazin C.
    J Clin Virol; 2011 Dec; 52(4):321-7. PubMed ID: 21924672
    [Abstract] [Full Text] [Related]

  • 9. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á, García-González X, Rodríguez-González CG, Ochoa-Palominos A, Sanjurjo-Sáez M, Clemente-Ricote G.
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C.
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.
    Park C, Jiang S, Lawson KA.
    J Clin Pharm Ther; 2014 Feb; 39(1):14-24. PubMed ID: 24237070
    [Abstract] [Full Text] [Related]

  • 19. New developments in HCV therapy.
    Kronenberger B, Zeuzem S.
    J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414
    [Abstract] [Full Text] [Related]

  • 20. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C, Jesudian A, Zeuzem S, Jacobson I.
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.